ATN研究框架与路易体痴呆患者的临床特征、认知衰退和死亡率的关联
研究纳入202例路易体痴呆患者,按脑脊液β-淀粉样蛋白42、p-tau及内侧颞叶萎缩评分分为8种ATN画像。57%属AD连续谱,其记忆衰退更陡、死亡风险更高;非AD病理改变与正常AD生物标志物组间认知衰退和死亡率无差异。
要点
- 57%的路易体痴呆患者ATN画像属AD连续谱,25%AD生物标志物正常。
- A+类别患者记忆测验衰退更陡、死亡风险高于AD生物标志物正常者。
- 非AD病理改变与正常AD生物标志物组间认知衰退和死亡率无差异。
核心结论
- 在路易体痴呆队列中,ATN分类与疾病表现存在临床相关关联,AD连续谱患者认知衰退更陡、生存期更短。
研究设计与样本
- 纳入阿姆斯特丹痴呆队列202例路易体痴呆患者(68±7岁,女性19%,简易精神状态检查24±3,DAT-SPECT异常105/119),按脑脊液β-淀粉样蛋白42、脑脊液p-tau和内侧颞叶萎缩评分分为8种ATN画像。
主要发现
- 202例中50例(25%)AD生物标志物正常(A-T-N-),37例(18%)为非AD病理改变(A-T+N- 10%、A-T-N+ 6%、A-T+N+ 3%),115例(57%)属AD连续谱(A+T-N- 20%、A+T+N- 16%、A+T-N+ 10%、A+T+N+ 9%)。
- A+T+N+患者年龄更大且REM睡眠行为障碍症状最少见;帕金森综合征在A+T-较A-T+患者更常见(独立于N)。
- 与AD生物标志物正常者相比,A+类别患者在记忆测验上衰退更陡且死亡风险更高;非AD病理改变与正常AD生物标志物组间认知衰退和死亡率无差异。
关键数值与推荐
- 认知测验随访3±2年(n=139),采用线性混合模型分析衰退;死亡率采用Cox比例风险分析。
临床怎么用
- 作者认为,在路易体痴呆患者中实施ATN框架有助于基于潜在生物学过程进行亚型划分,并可能为未来治疗策略(如AD修饰治疗)提供靶点。
- 作者认为,纳入α-突触核蛋白病标志物扩展该框架将改善对混合病理痴呆患者的特征描述,并可能增强治疗试验的患者分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The ATN framework has been developed to categorize biological processes within the Alzheimer disease (AD) continuum. Because AD pathology often coincides with dementia with Lewy bodies (DLB), we aimed to investigate the distribution of ATN profiles in DLB and associate ATN profiles in DLB with prognosis. METHODS: We included 202 patients with DLB from the Amsterdam Dementia Cohort (68±7 years; 19% female; Mini-Mental State Examination 24 ± 3; abnormal DAT-SPECT 105/119). Patients were classified into 8 profiles according to the ATN framework, using CSF β-amyloid (Aβ)42 (A), CSF p-tau (T), and medial temporal atrophy scores (N). We compared presence of clinical symptoms in ATN profiles and used linear mixed models to analyze decline on cognitive tests (follow-up 3±2 years for n = 139). Mortality risk was assessed using Cox proportional hazards analysis. Analyses were performed on the 8 profiles as well as 3 clustered categories (normal AD biomarkers, non-AD pathologic change, and AD continuum). RESULTS: Fifty (25%) patients with DLB had normal AD biomarkers (A-T-N-), 37 (18%) had non-AD pathologic change (A-T+N- 10%, A-T-N+ 6%, A-T+N+ 3%), and 115 (57%) were classified within the AD continuum (A+T-N- 20%, A+T+N- 16%, A+T-N+ 10%, A+T+N+ 9%). A+T+N+ patients were older and least often had REM sleep behavior disorder symptoms. Parkinsonism was more often present in A+T- compared to A-T+ patients (independent of N). Compared to patients with normal AD biomarkers, patients in A+ categories showed steeper decline on memory tests and higher mortality risk. Cognitive decline and mortality did not differ between non-AD pathologic change and normal AD biomarkers. DISCUSSION: In our DLB cohort, we found clinically relevant associations between ATN categories and disease manifestation. Patients within the AD continuum had steeper cognitive decline and shorter survival. Implementing the ATN framework within patients with DLB aids in subtyping patients based on underlying biological processes and could provide targets for future treatment strategies (for example, AD-modifying treatment). Expanding the framework by incorporating markers for α-synucleinopathy would improve the use of the framework to characterize patients with dementia with mixed pathology, which could enhance proper stratification of patients for therapeutic trials.
引用
- van de Beek M, Ooms FAH, Ebenau JL, et al. Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology. 2022. PMID: 35074893. doi:10.1212/WNL.0000000000200048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。